SCHEMBL4770201

SCHEMBL4770201

O=C(Nc1ccc2c(c1)CCN(C1CCC1)CC2)c1ccc2nccnc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.50
RAB9A P51151 7/20 0.50
MAPT P10636 7/20 0.50
NPC1 O15118 6/20 0.50
ALDH1A1 P00352 5/20 0.50
TP53 P04637 3/20 0.50
GAA P10253 2/20 0.50
HRH3 Q9Y5N1 8/20 0.48
NFKB1 P19838 3/20 0.47
NFKB2 Q00653 3/20 0.47
RELA Q04206 3/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
KLK7 P49862 1/20 0.47
LMNA P02545 2/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772409 0.87 RAB9A (0.51) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4765563 0.84 RAB9A (0.53) SMN1; SMN2RAB9AMAPTNPC1TP53
SCHEMBL4768020 0.84 SLC2A1 (0.53) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4770268 0.82 CREBBP (0.55) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4775503 0.82 MAPT (0.54) SMN1; SMN2RAB9AMAPTNPC1TP53
SCHEMBL4765111 0.82 HRH3 (0.46) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4765905 0.81 NPC1 (0.69) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4768058 0.81 NPC1 (0.69) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4765225 0.81 HRH3 (0.55) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1
SCHEMBL4774510 0.81 RAB9A (0.57) SMN1; SMN2RAB9AMAPTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP claimed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US claimed
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists HRH3, HRH4, HRH1 SMN1; SMN2 2487/4885RAB9A 2307/4885MAPT 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.